Affymax (AFFY) wins approval for its drug to treat anemic kidney patients -Bloomberg
Affymax (Nasdaq: AFFY) wins approval for its drug to treat anemic kidney patients
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sanofi (SNY) Terminates Option, License Agreement for Ardelyx's (ARDX) NaP2b Inhibitors Portfolio
- Dicerna Pharma (DRNA) Submits DCR-PH1 IND to U.S. FDA
- Innocoll AG (INNL) Doses First Patient in MATRIX-1 Phase 3
Create E-mail Alert Related CategoriesFDA, Momentum Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!